HB 1275: Medical practice; ensure that stem cell therapies are used to advance medical treatments and improve patient outcomes in an ethical manner that does not involve stem cells derived from aborted fetuses

In plain language

What the bill does

Who it affects

Why it matters

Key provisions

From the bill

Discussed in meetings (16)

The House and Senate meetings that took this bill up, from their machine transcripts. Each account was written by Georgia Commons with AI and is not part of the record; the video is what was said.

1. House Health Committee, February 23, 2026

   From 0:18:11 · Watch on the General Assembly's Vimeo channel

   Summary by Georgia Commons: The sponsor said HB 1275 would allow regulated Georgia companies to manufacture and distribute stem cell products within Georgia, reducing reliance on out-of-state suppliers. The sponsor described donated human birth tissue, including umbilical cords, and said the bill excludes tissue derived from abortions. Members asked about tissue donation, research restrictions, costs and insurance. The sponsor described voluntary donations without payment to donors or physicians. An internal medicine physician supported local access. A pain-management physician reported longer-lasting relief than steroid injections, said the cells generally cost $500 to $1,000, and said treatment was not covered by insurance. Representatives of the Catholic Bishops of Georgia and Georgia Baptist Mission Board supported the bill's ethical restrictions. An Emory witness supported its intent but sought protection for ongoing research, particularly animal stem cell research. The sponsor agreed to add human before references to stem cells throughout the bill. The committee approved that amendment and the bill. Two opposing votes on the bill were reported.

2. House Rules Committee, February 25, 2026

   From 1:35:05 · Watch on the General Assembly's Vimeo channel

   Summary by Georgia Commons: The sponsor said HB 1275 would allow stem cell therapy materials to be retrieved, processed and manufactured in Georgia, rather than obtained only from other states. One member questioned whether language requiring retrieval, manufacture and storage in Georgia would restrict interstate commerce and limit access to treatment. The sponsor said the intent was to regulate work done in Georgia through facilities registered with the FDA or overseen by other accrediting organizations, not to bar out-of-state materials. The member asked about deleting the reference to Georgia, and the sponsor expressed no objection. A second member agreed that the wording appeared restrictive and could hinder patients' access. The sponsor offered to revise the language. Later, the sponsor moved to return the bill to the Health Committee, and the chair declared it recommitted without stated opposition.

3. House Health Committee, February 25, 2026

   From 0:21:01 · Watch on the General Assembly's Vimeo channel

   Summary by Georgia Commons: The sponsor brought HB 1275 back after its return to committee, describing it as regulating regenerative medicine, including stem cell therapy, within ethical limits. The sponsor presented a revised substitute correcting language that could have appeared to exclude materials from outside Georgia. The sponsor said the revision expressly allowed materials from another state or country while retaining the proposal's requirements, including registration with the FDA or another listed accrediting organization. Asked about the distinction between human and animal materials, the sponsor said an earlier committee amendment addressing that issue was already incorporated. One member who had previously voted against the proposal thanked the sponsor for correcting the geographic restriction. Another member sought consideration of a Medicaid expansion amendment. The sponsor offered to discuss that separately, and the chair declined to accept the amendment. The committee approved the revised proposal by voice vote; no count was stated.

4. House Rules Committee, March 2, 2026

   From 1:12:38 · Watch on the General Assembly's Vimeo channel

   Summary by Georgia Commons: The sponsor said HB 1275 would allow stem cell therapies to be produced and distributed in Georgia. The sponsor explained that the measure had returned to committee to correct language that appeared to exclude out-of-state sources already in use, and presented the corrected version. No questions or decision followed.

5. House Rules Committee, March 4, 2026

   From 1:55:05 · Watch on the General Assembly's Vimeo channel

   Summary by Georgia Commons: The committee placed HB 1275 on the day's floor calendar under modified rules without opposition. Its provisions were not discussed.

6. House floor session, March 4, 2026 (legislative day 27, AM)

   From 2:21:07 · Watch on the General Assembly's Vimeo channel · Confirmed by the 2026 House Journal, p. 1840

   Summary by Georgia Commons: The sponsor said HB 1275 would allow Georgia companies to ethically source, manufacture and distribute stem-cell products in the state. The sponsor said Georgia currently allowed distribution but required manufacturing outside the state, while Utah and Florida had allowed in-state production. The sponsor described developing uses for joint pain and wound healing and argued that the change would improve access and reduce reliance on out-of-state providers. No members asked questions. The House adopted the committee substitute and passed the bill, 172 to 0.

7. Senate Health and Human Services Committee, March 23, 2026

   From 1:06:30 · Watch on the General Assembly's Vimeo channel

   Summary by Georgia Commons: The sponsor said the substitute would allow Georgia processing of donated umbilical-cord and placental tissue for stem cell therapies, reducing reliance on out-of-state shipments. The sponsor said it excluded material from aborted fetuses or embryos, required disclosure that therapies lacked FDA approval, and preserved federally compliant research. A Point8 Therapeutics witness described hepatitis testing and three rounds of sterility testing under FDA standards. Members questioned protections for research and overlap with existing investigational-treatment law. The sponsor said current law did not permit the processing contemplated here. A Georgia Baptist Mission Board witness supported the ethical restrictions. A Georgia Fertility Network witness warned that ambiguous embryo language could affect IVF, discourage research and expose patients to unproven treatments. That witness requested removing the term embryo and specifying umbilical-cord material. The sponsor maintained that the bill would not change what treatments were legal. At the sponsor's request, members adopted changes deleting one listed provision and removing the National Marrow Donor Program from the accreditation list because, the sponsor said, it did not perform that function. The amendment and amended substitute passed unanimously.

8. Senate Rules Committee, March 25, 2026

   From 0:41:34 · Watch on the General Assembly's Vimeo channel

   Summary by Georgia Commons: A committee member selected HB 1275 for the calendar. No provisions were discussed. The committee unanimously approved the calendar package containing the bill.

9. Senate floor session, March 27, 2026 (legislative day 38)

   From 8:40:59 · Watch on the General Assembly's Vimeo channel · Confirmed by the bill's status history (Senate Tabled)

   Summary by Georgia Commons: The sponsor said HB 1275 would authorize physicians, and physician-designated physician assistants and nurse practitioners, to perform human stem cell therapies not approved by the FDA. The clerk described patient protections, notice and consent provisions, and restrictions against using cells derived from aborted fetuses. No questions or opposition followed. The Senate adopted the committee substitute and passed the bill 48-0.

10. House floor session, March 31, 2026 (legislative day 39, part 2)

    From 3:24:38 · Watch on the General Assembly's Vimeo channel · Confirmed by the bill's status history (House Agreed Senate Amend or Sub)

    Summary by Georgia Commons: The presenter said the bill allowed ethically obtained stem cell therapies to be produced and distributed in Georgia. The presenter said the Senate added a clarification that the bill did not regulate, restrict or prohibit research already underway through the FDA or institutions such as medical schools. No members asked questions. The House agreed to the Senate substitute, 166 to 1.

• Read aloud: House floor session, February 12, 2026 (legislative day 18), 0:45:54
• Read aloud: House floor session, February 17, 2026 (legislative day 19), 0:57:08
• Read aloud: House floor session, February 24, 2026 (legislative day 23), 0:50:43
• Read aloud: House floor session, February 26, 2026 (legislative day 25, AM), 1:06:42
• Read aloud: Senate floor session, March 6, 2026 (legislative day 28, part 1), 0:40:19
• Read aloud: Senate floor session, March 25, 2026 (legislative day 37), 0:34:04

Status timeline

Sponsors

Votes

Topics